Drug Trial Radar · NCT03580044
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
Last checked: Nov 20, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15
Actual
Start
Dec 25, 2020
Primary completion
Jan 23, 2023
Study completion Jan 23, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Allergan
- First posted
- Jul 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-β-lactamase (MBL)- producing Gram-negative bacteria.
Conditions
- Serious Bacterial Infection
Interventions
ATM-AVICombination product
ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
BATDrug
The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinical Cure at the Test of Cure (TOC) Visit -Microbiological Intent to Treat (Micro-ITT) Analysis SetTime frame: Day 28
Locations
42 sites in 12 countries. Site status is shown where the registry gives one.
Banner University Medical Center Tucson
Tucson, Arizona
Hospital San Roque
Córdoba, Argentina
The First Hospital of Kunming
Kunming, China
The First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
Hunan Province People's Hospital
Changsha, Hunan, China
Baotou Central Hospital
Baotou, Inner Mongolia, China
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
The First Hospital of Kunming
Kunming, Yunnan, China
General Hospital of Athens "Evangelismos"
Athens, Greece
General and Chest Diseases Hospital "Sotiria"
Athens, Greece
General Hospital of Athens "Laiko",
Athens, Greece
University General Hospital "ATTIKON", Medicine and Infectious Diseases
Athens, Greece
University General Hospital of Heraklion
Heraklion, Crete, Greece
University General Hospital of Larissa
Larissa, Greece
Victoria Hospital, Bangalore Medical College and Research Institute
Bangalore, India
Government medical College
Kozhikode, Kerala, India
Deenanath Mangeshkar Hospital And Research Centre
Pune, Maharashtra, India
S.R.Kalla Memorial Gastro & General Hospital
Jaipur, Rajasthan, India
Apollo Hospitals Enterprise Limited
Chennai, Tamil Nadu, India
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Kuala Lumpur, Malaysia
Hospital Civil de Guadalajara "Fray Antonio Alcalde"
Guadalajara, Jalisco, Mexico
Davao Doctors Hospital
Davao City, Philippines
Makati Medical Center
Makati City, Philippines
Manila Doctors Hospital
Manila, Philippines
St. Luke's Medical Center
Quezon City, Philippines
Institutul National de Boli Infectioase "Prof. Dr. Matei Bals"
Bucharest, Romania
Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes"
Bucharest, Romania
Spitalul Clinic de Boli Infectioase Cluj Napoca
Cluj-Napoca, Romania
Spitalul Clinic de Boli Infectioase "Sf. Parascheva" Iasi
Iași, Romania
Spitalul Clinic Judetean de Urgenta "Pius Brinzeu"
Timișoara, Romania
SBHI of the city of Moscow "N.I.Pirogov City Clinical Hospital # 1"
Moscow, Russia
OGBUZ "Smolensk Regional Clinical Hospital"
Smolensk, Russia
FSBEI of HE "Smolensk State Medical University" of the Ministry of Health of the RF
Smolensk, Russia
SRI of Antimicrobial Chemotherapy
Smolensk, Russia
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Faculty of Medicine Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
Bamrasnaradura Infectious Disease Institute (BIDI)
Muang, Changwat Nonthaburi, Thailand
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.